Menu
Wechat public account

About CapitalBio

Management team
Dr. Jing Cheng
Chairman and President, CapitalBio Corporation
Member, Chinese Academy of Engineering

Dr. Jing Cheng is a Member of the Chinese Academy of Engineering and a Member of the International Eurasian Academy of Sciences. He received his Bachelor of Engineering degree in Electrical Engineering from Shanghai Tiedao University (now Tongji University) in 1983. He earned his Ph.D. in Forensic Science from the University of Strathclyde, United Kingdom, in 1992. From 1992 to 1996, he conducted postdoctoral research at the University of Strathclyde, the Department of Molecular and Cell Biology at the University of Aberdeen, and the Department of Pathology and Laboratory Medicine at the University of Pennsylvania School of Medicine. From 1996 to 2000, he served successively as Research Assistant Professor at the University of Pennsylvania, Principal Scientist at Nanogen, Inc., and Technical Director at AVIVA Biosciences. He currently holds the position of Chair Professor at Tsinghua University, Director of the Digital and Intelligent TCM Engineering Research Center at the School of Biomedical Engineering, Tsinghua Medicine, and Director of the National Engineering Research Center for Beijing Biochip Technology. He is also the Founder, Chairman, and President of CapitalBio Corporation. He is a Fellow of the Chinese Academy of Medical Sciences, a Fellow of the China Academy of Chinese Medical Sciences, and a Fellow of the American Institute of Medical and Bioengineering.


Dr. Cheng has published over 180 peer-reviewed SCI papers in prestigious journals, including Nature Biotechnology, Nature Communications, and the American Journal of Human Genetics. Since returning to China, he has authored or edited 4 monographs in Chinese and 4 in English. He holds more than 400 patents worldwide and has obtained 161 medical device registration certificates and 96 CE-IVD certificates. He has led the development of 27 national and industry standards. He has received numerous prestigious awards, including: the Second Prize of the National Award for Technological Invention (2007 and 2018, both as the first contributor); the Beijing Overseas Returnee Entrepreneur Award (2001); the Award for Outstanding Chinese Returnees (2003); the Qiushi Outstanding Youth Achievement Transformation Award (2004); the China Youth Science and Technology Award (2004); the C.C. Tan Life Science Innovation Award (2008); the Ho Leung Ho Lee Prize for Scientific and Technological Innovation (2008); the China Overseas Returnee Entrepreneurship and Take-off Award (2010); the Capital Science and Technology Gala - Top Ten Scientific Figures Driving "Beijing Creation" (2012); the 2014 China Science Newsmaker of the Year; the Chinese Academy of Engineering Guanghua Engineering Science and Technology Award (2014); the China Top Engineer Award (2014); the First Prize of the Maternal and Child Health Science and Technology Achievement Award (2015); the C.C. Tan Life Science Achievement Award (2016); the Huang Jiasi Biomedical Engineering Award (First Prize, 2017, 2023, and 2025); the Outstanding Contribution Award for Translational Medicine (2018); the Shulan Medical Prize (2018); the National Innovation Excellence Award (2020); the Beijing Advanced Individual in COVID-19 Prevention and Control (2020); the CAETS Communications Prize for Engineering Success Stories (2021); the Second Prize of the Huaxia Medical Science and Technology Award (2024); and the First Prize of the International Contribution Award for Chinese Medicine - Scientific and Technological Progress Award (2024). He is a recipient of the Special Government Allowance of the State Council.




Copyright © 2000-2023博奥生物集团有限公司 京ICP备14023013号-3

《互联网药品信息服务资格证书》: (京) - 非经营性-2016-0047 京公网安备11011402013114号